We use cookies to enhance your browsing experience, analyze website traffic, and maintain essential site functionality. By clicking "Accept All", you consent to our use of cookies. For more details, please review our Privacy Policy.

Eton Pharmaceuticals Stock (NASDAQ:ETON)



Previous Close

$17.12

52W Range

$3.18 - $21.48

50D Avg

$14.72

200D Avg

$11.12

Market Cap

$528.30M

Avg Vol (3M)

$256.00K

Beta

1.23

Div Yield

-

ETON Company Profile


Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

31

IPO Date

Nov 13, 2018

Website

ETON Performance


Total Return %
1D
5D
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
ETON
S&P 500
15.07%
12.76%
39.91%
19.98%
96.61%
37.67%
439.73%
513.71%
319.15%
215.20%
0.49%
4.23%
12.33%
-3.16%
0.80%
1.00%
11.68%
47.58%
100.16%
177.08%

Latest Earnings Call Transcripts


Q2 22Aug 12, 22 | 4:27 AM
Q4 21Mar 16, 22 | 10:50 PM
Q3 21Nov 15, 21 | 9:07 PM

Peer Comparison


TickerCompany
LIANLianBio
ELVNEnliven Therapeutics, Inc.
GOSSGossamer Bio, Inc.
ALDXAldeyra Therapeutics, Inc.
MACKMerrimack Pharmaceuticals, Inc.
CELCCelcuity Inc.
ALECAlector, Inc.
BDTXBlack Diamond Therapeutics, Inc.
REPLReplimune Group, Inc.
PASGPassage Bio, Inc.
LYRALyra Therapeutics, Inc.
KRONKronos Bio, Inc.
CNTBConnect Biopharma Holdings Limited

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools